Sign inJoin waitlistJoin the waitlist

Michael Guy

Associate Professor of Clinical · University of Cincinnati Medical Center Inc.

Credentials: · · · · ·

History

University of Cincinnati Medical Center Inc.
Present

Gynecologic Oncology
University of Colorado School of Medicine
2018–2021
Memorial Sloan Kettering Cancer Center
2014–2018
Northeastern Ohio Medical University
2011–2014
Akron General Medical Center
2008–2011
Boonshoft School of Medicine - Wright State University
2004–2008
University of Dayton (Biology

Research

Animal models of arthritis: relevance to human disease
Toxicologic Pathology · 1999 · Last of 7 authors · 213 citations
Preparedness of Obstetrics and Gynecology Residents for Fellowship Training
Obstetrics and Gynecology · 2015 · 106 citations
Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women
Ultrasound in Obstetrics and Gynecology · 2022 · 83 citations

Jeanelle Sheeder
8 papers
Kian Behbakht
7 papers
Saketh Guntupalli
6 papers · 6 as a fellow
David Doo
3 papers · 3 as a resident
SD
Susan Davidson
3 papers
MJ
Michael Jarrett
2 papers · 1 as a resident
Miriam Post
2 papers
Monique Spillman
2 papers
AH
Adam Hiett
1 paper
Aparna Kamat
1 paper
Bradley Corr
1 paper · 1 as a fellow
Brian Slomovitz
1 paper

Clinical trials

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Site PI · Recruiting · Phase 2
Acrivon Therapeutics
2022–2027